OABI — OmniAb, Inc.

Summary of OmniAb, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $8.4 million, down from $10.8 million in Q4 2024, primarily due to a decline in license revenue, partially offset by increased milestone revenue.
• Full Year 2025 Revenue: $18.7 million, compared to $26.4 million in 2024, attributed to decreased license and milestone revenue.
• Net Loss: Q4 net loss of $14.2 million ($0.11 per share) compared to a net loss of $13.1 million ($0.12 per share) in Q4 2024. Full year net loss was $64.8 million ($0.57 per share) versus $62 million ($0.61 per share) in 2024.
• Operating Expenses: Decreased to $24.1 million in Q4 from $26.7 million, and full-year expenses dropped to $87.6 million from $100.9 million, largely due to lower personnel costs.
• Cash Position: Ended 2025 with $54 million in cash and equivalents, expecting to finish 2026 with $30 million to $35 million.

2. Strategic Updates and Business Highlights

• Partner Growth: Ended 2025 with 107 partners and 407 active programs, a net increase of 44 programs during the year.
• New Technologies: Launched OmniUltra, a transgenic chicken platform for ultra-long CDRH3 antibodies, and xPloration, a high-throughput single B-cell screening platform, both expected to drive future growth.
• Clinical Progress: 25 advancement events in 2025, including 16 programs moving to preclinical development and 4 to Phase I trials, indicating strong partner engagement and program progression.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $25 million and $30 million, reflecting anticipated milestones and partner disclosures.
• Operating Expenses: Projected to range from $80 million to $85 million, with cash operating expenses expected to be $50 million to $55 million.
• Long-term Outlook: Emphasis on transitioning revenue from milestone-driven to more royalty-driven streams, with over $3 billion in contracted milestones and an average royalty rate of 3.4%.

4. Bad News, Challenges, or Points of Concern

• Declining Revenue: Significant decrease in both quarterly and annual revenue compared to previous years, raising concerns about the sustainability of growth.
• Net Losses: Continued net losses, although slightly improved on a per-share basis, indicate ongoing financial challenges.
• Market Conditions: Potential impact from broader market fundraising activities and economic conditions on partner spending and program initiation.

5. Notable Q&A Insights

• Partner Program Growth: Management expressed optimism about new program growth in 2026, driven by recent technology launches and strong partner engagement.
• xPloration Revenue Potential: Initial deployments of xPloration are promising, with expectations for significant growth in revenue from this platform, although specific numbers were not disclosed.
• Cash Flow Breakeven: While management is optimistic about reaching cash flow breakeven, they did not provide a specific timeline, indicating it depends on the progression of partner programs.
• Royalty Structures: Most existing agreements are based on flat royalties, with some tiered structures, and management indicated they aim to command higher royalties for newer technologies.

Overall, while OmniAb has made significant strides in expanding its partner base and launching innovative technologies, it faces challenges in revenue generation and profitability that will need to be addressed moving forward.